Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Menicon Co., Ltd. (7780.T)
JPY1,680.00
+5.00 (+0.30%)
JP JPX Healthcare Medical - Instruments & Supplies
Address
3-21-19, Aoi 460-0006
Nagoya, JP
Nagoya, JP
CEO
Koji Kawaura
Website
menicon.co.jp
IPO
2015-06-25
ISIN JP3921270009
Description
Menicon Co., Ltd. is a company dedicated to the manufacturing and global distribution of contact lenses and their essential care solutions. The firm supplies its range of eye care products to a diverse network of outlets, including medical facilities like hospitals and ophthalmology clinics, as well as retail channels such as specialized contact lens stores, eyewear retailers, and pharmacies. With a substantial international presence, Menicon extends its reach to over 80 countries, encompassing major markets in the United States, Europe, Oceania, and Asia. This Japanese entity, which was founded in 1943, is based in Nagoya.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY1,680.00
+5.00 (+0.30%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
243.3K
Beta
0.60
Float Shares
59.36M
Free Float %
80.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.38% | -5.59% | -10.11% | -15.63% | +14.01% | -2.35% | +22.16% | -44.91% | -54.36% | +77.55% | +139.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,680.00
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.30
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+3.4% Q1'26: +5.6% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+13.8% Q1'26: -183.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+1.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+8.2% Q1'26: +3.9% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.0% Q1'26: +2.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-7.9% ★ Q1'26: -1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.52× Q1'26: 4.09× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 6 EPS Ana. |
Mar 2027 6 Rev. Ana. 6 EPS Ana. |
Mar 2028 5 Rev. Ana. 5 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
67.33B
est: 67.90B (-0.8%)
|
72.05B
est: 72.50B (-0.6%)
|
76.67B
est: 76.80B (-0.2%)
|
80.90B
est: 81.25B (-0.4%)
|
84.52B
est: 84.90B (-0.4%)
|
86.21B
est: 86.94B (-0.8%)
|
100.17B
est: 100.15B (+0.0%)
|
110.19B
est: 109.66B (+0.5%)
|
116.19B
est: 117.90B (-1.4%)
|
121.49B
est: 122.37B (-0.7%)
|
125.57B
124.83B – 126.45B
+2.6% YoY
|
131.31B
128.88B – 134.09B
+4.6% YoY
|
136.78B
131.79B – 141.28B
+4.2% YoY
|
141.00B
138.95B – 143.05B
+3.1% YoY
|
148.00B
143.91B – 152.02B
+5.0% YoY
|
| EBITDA |
8.44B
est: 10.89B (-22.5%)
|
9.07B
est: 11.63B (-22.0%)
|
9.40B
est: 12.32B (-23.7%)
|
10.21B
est: 13.04B (-21.7%)
|
11.87B
est: 13.62B (-12.8%)
|
14.14B
est: 13.95B (+1.3%)
|
17.53B
est: 16.07B (+9.1%)
|
19.33B
est: 17.59B (+9.9%)
|
15.74B
est: 18.92B (-16.8%)
|
18.53B
est: 19.63B (-5.6%)
|
20.15B
20.03B – 20.29B
+2.6% YoY
|
21.07B
20.68B – 21.51B
+4.6% YoY
|
21.94B
21.14B – 22.67B
+4.2% YoY
|
22.62B
22.29B – 22.95B
+3.1% YoY
|
23.75B
23.09B – 24.39B
+5.0% YoY
|
| EBIT |
4.08B
est: 6.16B (-33.9%)
|
4.42B
est: 6.58B (-32.9%)
|
4.50B
est: 6.97B (-35.4%)
|
5.57B
est: 7.38B (-24.4%)
|
6.45B
est: 7.71B (-16.3%)
|
8.11B
est: 7.89B (+2.7%)
|
10.23B
est: 9.09B (+12.5%)
|
11.88B
est: 9.96B (+19.3%)
|
7.79B
est: 10.70B (-27.2%)
|
10.08B
est: 11.11B (-9.3%)
|
11.40B
11.33B – 11.48B
+2.6% YoY
|
11.92B
11.70B – 12.17B
+4.6% YoY
|
12.42B
11.97B – 12.83B
+4.2% YoY
|
12.80B
12.62B – 12.99B
+3.1% YoY
|
13.44B
13.07B – 13.80B
+5.0% YoY
|
| Net Income |
2.22B
est: 2.36B (-5.6%)
|
2.54B
est: 2.55B (-0.3%)
|
2.66B
est: 3.60B (-26.1%)
|
3.58B
est: 3.88B (-7.9%)
|
4.06B
est: 5.37B (-24.4%)
|
5.95B
est: 5.78B (+3.0%)
|
6.48B
est: 6.90B (-6.0%)
|
7.38B
est: 8.15B (-9.5%)
|
4.54B
est: 5.06B (-10.4%)
|
5.62B
est: 7.29B (-22.9%)
|
7.29B
6.74B – 7.84B
+0.0% YoY
|
8.06B
7.35B – 8.77B
+10.5% YoY
|
8.12B
7.61B – 10.33B
+0.7% YoY
|
11.99B
9.40B – 14.58B
+47.8% YoY
|
14.19B
13.68B – 14.69B
+18.3% YoY
|
| SGA |
30.46B
est: 27.49B (+10.8%)
|
31.40B
est: 29.35B (+7.0%)
|
33.33B
est: 31.09B (+7.2%)
|
33.45B
est: 32.89B (+1.7%)
|
34.35B
est: 34.37B (0.0%)
|
34.13B
est: 35.20B (-3.0%)
|
39.00B
est: 40.54B (-3.8%)
|
42.10B
est: 44.39B (-5.2%)
|
46.93B
est: 47.73B (-1.7%)
|
55.03B
est: 49.54B (+11.1%)
|
50.83B
50.53B – 51.19B
+2.6% YoY
|
53.16B
52.17B – 54.28B
+4.6% YoY
|
55.37B
53.35B – 57.19B
+4.2% YoY
|
57.08B
56.25B – 57.91B
+3.1% YoY
|
59.91B
58.26B – 61.54B
+5.0% YoY
|
| EPS |
31.26
est: 28.89 (+8.2%)
|
35.88
est: 31.26 (+14.8%)
|
37.83
est: 44.10 (-14.2%)
|
47.15
est: 47.60 (-0.9%)
|
56.11
est: 65.83 (-14.8%)
|
78.81
est: 70.80 (+11.3%)
|
85.71
est: 84.53 (+1.4%)
|
97.24
est: 100.04 (-2.8%)
|
59.63
est: 62.07 (-3.9%)
|
74.02
est: 89.38 (-17.2%)
|
88.40
82.57 – 96.15
-1.1% YoY
|
96.51
90.11 – 107.46
+9.2% YoY
|
112.73
93.26 – 126.64
+16.8% YoY
|
147.00
115.27 – 178.73
+30.4% YoY
|
173.90
167.65 – 180.04
+18.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.49B
OE per share TTM
30.64
Owner's Yield
2.17%
Maintenance CapEx ratio
58.04%
Maint CapEx / Avg PPE
52.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 81 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.08% | 255.3K | 0.31% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.07% | 624.6K | 0.40% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.06% | 566.1K | 0.40% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.05% | 123.9K | 0.50% |
| 5 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.05% | 266.2K | 0.58% |
| 6 | Dimensional - International Small Cap ETF DFIS | 0.04% | 2.26M | 0.39% |
| 7 | iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE | 0.03% | 133.4K | 0.10% |
| 8 | Schwab Fundamental International Small Company Index ETF FNDC | 0.03% | 865.5K | 0.39% |
| 9 | Avantis International Small Cap Equity ETF AVDS | 0.03% | 88.6K | 0.30% |
| 10 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.02% | 197.2K | 0.23% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.43M
Shares Outstanding
74.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideki Koga | Senior Executive Officer, Director of Corporate Management Head Office & CFO | — | male |
| Kenji Takeshita | Senior Executive Officer & Head of Domestic Sales Management Office | — | male |
| Kensuke Muraki | Senior Executive Officer & Head of the Miru Mirai Business Management Headquarters | — | male |
| Koji Kawaura | Representative Executive Officer, President, Chief Executive Officer & Director | — | male |
| Motonari Watanabe | Senior Executive Officer and Director of Manufacturing, R&D Head Office | — | male |
| Nicolaas Johannes Adrianus Engelhart | Senior Executive Officer & Director of International Business Head Office | — | male |
| Oxana Pastushenko | Chief Executive Officer of EMEA | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7780.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
